Biopharmaceutical company NeoStem (NASDAQ:NBS) said Wednesday that it will be presenting at two upcoming conferences this month in New York.
The company, founded in 1980 and with about 611 employees, develops cellular therapies for oncology, immunology and regenerative medicines in China and the United States.
It provides adult stem cell collection, processing, and storage services that allow healthy individuals to donate and store their stem cells for personal therapeutic use.
New York-based NeoStem also said that Progenitor Cell Therapy, which the company acquired last year, will also be presenting at one of the February conferences.
NeoStem’s chief executive, Robin L. Smith, will be providing a corporate update on February 14 at the Bio CEO & Investor Conference at 9:30 a.m. at the Waldorf Astoria Hotel, in New York City.
In addition, Progenitor Cell Therapy’s president, Robert A. Preti will be presenting at the New York Stem Cell Summit, where he will talk about its contract manufacturing services for the cell therapy industry. This conference will take place on February 21 at 11:41 a.m. at Bridgewaters, New York.
NeoStem’s CEO is also slated to make a presentation at the Bridgewaters event at 1:47 p.m.
Late last month, the company’s subsidiary, Amorcyte, announced that it enrolled the first patient in the PreSERVE phase 2 trial for its AMR-001 therapy, designed to treat patients post heart-attack.
The study is a multi-centre, double-blind, placebo-controlled clinical trial testing the safety and efficacy of the treatment by artery infusion.
AMR-001 is an autologous cell therapy designed to prevent heart tissue damage and further major adverse cardiac events following a heart attack.
The treatment consists of a patient's own bone marrow cells, which are processed to create pharmaceutical-grade cells which are then re-injected via coronary arteries into damaged areas of the heart, five to 11 days after a patient experiences a heart attack.
Because the treatment is autologous, meaning cells are taken from the same individual that they are transplanted into there is no risk of rejection and can provide support for an extended period of time.
NeoStem said that for the phase two study, roughly 160 subjects aged 18 or older will be randomized on a 1:1 basis between the treatment and control groups. Results are expected sometime in the middle of 2013.